Sweden-based Amniotics AB is in the early stages of developing a unique stem cell-based pipeline using amniotic fluid sourced from caesarean section births – an approach that is ethically sound and offers secure supply given the rising trend globally of C-section delivery, the biotech’s CEO has told Scrip.
Amniotics’ technology is based on collecting mesenchymal stem cells (MSC) from amniotic fluid, followed by a patent protected enhancement of...
Welcome to Scrip
Create an account to read this article
Already a subscriber?